// App-Quantinova.ai

: Isoniazid mono-resistance negatively affects tuberculosis treatment outcomes in Europe

Researchers

Presenter

  • Basel Karo

Principal Investigators

  • Anke Kohlenberg

  • Vahur Hollo

  • Raquel Duarte

  • Lena Fiebig

  • Sarah Jackson

  • Cathriona Kearns

  • Csaba Kdmn

  • Maria Korzeniewska-Kosela

  • Dimitrios Papaventsis

  • Ivan Solovic

  • Dick Van Soolingen

  • Marieke van der Werf

Medical Centers

  • Infectious Disease Department, Robert Koch Institute, Berlin, Germany

  • European Centre for Disease Prevention and Control, Stockholm, Sweden

  • Directorate General of Health, Porto, Portugal

  • Apopo, Sokoine University of Agriculture, Morogoro, Tanzania

  • Health Protection Surveillance Centre, Gardiner Street, Dublin, Ireland

  • Public Health Agency, Belfast, United Kingdom

  • National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

  • National Reference Laboratory for Mycobacteria, “Sotiria” Chest Diseases Hospital, Athens, Greece

  • National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Slovakia

  • Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, Netherlands

Locations

  • Germany

  • Sweden

  • Portugal

  • Tanzania

  • Ireland

  • United Kingdom

  • Poland

  • Greece

  • Slovakia

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Tuberculosis

Biomarkers

  • N/A

Drug/Treatment

  • Isoniazid

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved